 
 
Gas for Macular Hole Protocol V3.0 8 -12-19  
DRCR  Retina Network  
 
 
 
 
Single -Arm Study Assessing the Eff ects of 
Pneumatic Vitreolysis on Macular Hole  
(Protocol A H) 
 
 
IDE Sponsor: Jaeb Center for Health Research  (JCHR)  
 
Version  3.0 
 
12 August  2019  
 
[STUDY_ID_REMOVED]  
 
 
 
Gas for Macular Hole Protocol V3.0 8 -12-19 Signature Page  
Single -Arm Study Assessing the Effects of Pneumatic 
Vitreolysis on Macular Hole  
Protocol Identifying Number: DRCR Retina Network  AH 
IDE Sponsor: Jaeb Center for Health Research  
Version  Number: 3.0 
12 August  2019  
 
 
 
JCHR Principal Investigator   
Name, degree  Adam Glassman, M S  
 
Signature / Date   
 
 
 
 
 
 
 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 KEY ROLES  
 
Protocol Chair   
Name, degree  Calvin E. Mein, MD  
Title  Ophthalmologist  
Institution Name  Retinal Consultants of San Antonio, San Antonio, TX  
 
JCHR Coordinating Center Director   
Name, degree  Adam Glassman, MS  
Title  Director of DRCR Retina Network  Coordinating Center  
Institution Name  Jaeb Center for Health Research, Tampa, FL  
 
Network Chair   
Name, degree  Daniel F. Martin, MD  
Title  Chairman, Cole Eye Institute  
Institution Name  Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio  
 
Medical Monitor   
Name, Title  Robert Lindblad, Senior Medical Officer  
Ashraf El Fiky, Medical Officer  
Institution Name  The EMMES Corporation  
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 TABLE OF CONTENTS  
Chapter 1:  Background Information and Study Synopsis  ................................ ..........................  1-1 
1.1. Introduction  ................................ ................................ ................................ ...................  1-1 
1.1.1 Vitreoretinal Interface Abnormalities  ................................ ................................ .........  1-1 
1.1.2 Treatments for VMT  with Macular Hole  ................................ ................................ .... 1-1 
1.1.3 Pneumatic Vitreolysis (PVL)  ................................ ................................ ......................  1-1 
1.2. Rationale  ................................ ................................ ................................ ........................  1-2 
1.3 Study Objectiv es ................................ ................................ ................................ ...........  1-2 
1.4 Potential Risks and Benefits of C 3F8 Gas Injection  ................................ .......................  1-2 
1.4.1  Known Potential Risks  ................................ ................................ ..............................  1-2 
1.5 General Considerations  ................................ ................................ ................................ . 1-4 
Chapte r 2: Study Participant Eligibility and Enrollment  ................................ ...........................  2-1 
2.1 Participant Recruitment and Enrollment  ................................ ................................ ............  2-1 
2.2 Participant Eligibility Criteria  ................................ ................................ ............................  2-1 
2.2.1 Participant -Level Criteria ................................ ................................ ............................  2-1 
2.2.2 Study Eye Criteria  ................................ ................................ ................................ ....... 2-2 
2.3 Screening Evaluation and Baseline Testing  ................................ ................................ ....... 2-3 
2.3.1 Baseline Testing Procedures  ................................ ................................ .......................  2-3 
Chapter 3:  Baseline Treatment  ................................ ................................ ................................ ... 3-1 
3.1 Treatment  ................................ ................................ ................................ ...........................  3-1 
3.2 Injection Procedure  ................................ ................................ ................................ ............  3-1 
3.2.1 Intravitreous Injection Technique  ................................ ................................ ...............  3-1 
3.2.2 Aqueous Sample Collection  ................................ ................................ ........................  3-1 
3.3 Participant Instructions Post -Injection  ................................ ................................ ...............  3-1 
Chapter 4:  Follow -Up Visits and Testing  ................................ ................................ ..................  4-1 
4.1 Study Visits  ................................ ................................ ................................ ........................  4-1 
4.1.1 Procedures  at Study Visits  ................................ ................................ ..........................  4-1 
4.1.2 Unscheduled Visits  ................................ ................................ ................................ ..... 4-1 
4.2 Treatment During Follow Up ................................ ................................ .............................  4-1 
4.2.1 Criteria for Vitrectomy  ................................ ................................ ...............................  4-1 
4.2.2 Treatment for Other Conditions in the Study Eye  ................................ ......................  4-2 
4.2.3 Treatment in the Non -Study Eye  ................................ ................................ ................  4-2 
Chapter 5:  Study Device  ................................ ................................ ................................ ............  5-1 
5.2 Study Device Accountability Procedures  ................................ ................................ ..........  5-1 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 5.3 Safety Measures  ................................ ................................ ................................ .................  5-1 
Chapter 6:  Adverse Events, Device Issues, and Stopping Rules  ................................ ...............  6-1 
6.1 Adverse Events  ................................ ................................ ................................ ..................  6-1 
6.1.1 Definitions ................................ ................................ ................................ ...................  6-1 
6.1.2 Reportable Adverse Events  ................................ ................................ .........................  6-2 
6.1.3 Relationship of Adverse Event to Study Device ................................ .........................  6-2 
6.1.4 Intensity of Adverse Event ................................ ................................ ..........................  6-2 
6.1.5 Coding of Adverse Events  ................................ ................................ ..........................  6-3 
6.1.6 Outcome of Adverse Event  ................................ ................................ .........................  6-3 
6.2 Reportable Device Issues  ................................ ................................ ................................ ... 6-4 
6.3 Pregnancy Reporting  ................................ ................................ ................................ ..........  6-4 
6.4 Timing of Event Reporting  ................................ ................................ ................................  6-4 
6.5 Stopping Criteria  ................................ ................................ ................................ ................  6-4 
6.5.1 Criteria for Suspending or Stopping Overall Study  ................................ ....................  6-4 
6.6 Independent Safety Oversight  ................................ ................................ ............................  6-4 
6.7 Risks  ................................ ................................ ................................ ................................ ... 6-5 
Chapter 7:  Miscellaneous Considerations  ................................ ................................ ..................  7-1 
7.1 Prohibited Medications, Treatments, and Procedures  ................................ ........................  7-1 
7.2 Participant Withdrawal  ................................ ................................ ................................ ...... 7-1 
7.3 Discontinuation of Study  ................................ ................................ ................................ ... 7-1 
7.4 Confidentiality  ................................ ................................ ................................ ...................  7-1 
7.5 Participant Compensation  ................................ ................................ ................................ .. 7-1 
Chap ter 8:  Statistical Considerations  ................................ ................................ .........................  8-1 
8.4 Outcome Measures ................................ ................................ ................................ .............  8-1 
8.5 Analysis Cohorts  ................................ ................................ ................................ ................  8-2 
8.6 Analysis of the Primary Outcome  ................................ ................................ ......................  8-3 
8.7 Analysis of the Secondary and Exploratory Outcomes  ................................ .....................  8-3 
8.8 Safety Analyses  ................................ ................................ ................................ ..................  8-4 
8.9 Intervention Adherence  ................................ ................................ ................................ ...... 8-5 
8.10 Protocol Adherence and Retention  ................................ ................................ ..................  8-5 
8.11 Baseline Descriptive Statistics  ................................ ................................ .........................  8-5 
8.12 Planned Interim Analyses  ................................ ................................ ................................  8-5 
8.13 Subgroup Analyses  ................................ ................................ ................................ ..........  8-5 
8.14 Multiple Testing  ................................ ................................ ................................ ...............  8-6 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 Chapter 9:  Data Collection and Monitoring  ................................ ................................ ...............  9-1 
9.1 Case Report Forms and Device Data  ................................ ................................ .................  9-1 
9.2 Study Records Retention ................................ ................................ ................................ .... 9-1 
9.3 Quality Assurance and Moni toring  ................................ ................................ ....................  9-1 
9.4 Protocol Deviations  ................................ ................................ ................................ ............  9-2 
Chapter 10:  Ethics/Protection of Human Participants  ................................ .............................  10-1 
10.1 Ethics/Protection of Human Participants Ethical Standard  ................................ ...........  10-1 
10.2 Institutional Review Boards  ................................ ................................ ...........................  10-1 
10.3 Informed Consent Process  ................................ ................................ .............................  10-1 
10.3.1 Consent Procedures and Documentation  ................................ ................................  10-1 
10.3.2 Participant and Data Confidentiality  ................................ ................................ ....... 10-1 
10.3.3 Future Use of Stored Specimens  ................................ ................................ .............  10-2 
Chapter 11:  References  ................................ ................................ ................................ ............  11-1 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
AUC  Area Under the Curve  
CI Confidence Interval  
CRF  Case Report Form  
DSMC  Data and Safety Monitoring Committee  
E-ETDRS  Electronic -Early Treatment Diabetic Retinopathy Study  
ERM  Epiretinal Membrane  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
ICH International Conference on Harmonization   
ID Identification  
IDE Investigational Device Exemption  
IOP Intraocular Pressure  
IRB Institutional Review Board  
ITT Intention -To-Treat  
JCHR  Jaeb Center for Health Research  
MH Macular Hole  
OCT  Optical Coherence Tomography  
PVD  Posterior Vitreous Detachment  
PVL  Pneumatic Vitreolysis  
SADE  Serious Adverse Device Event  
SAE  Serious Adverse Event  
SD Standard Deviation  
UADE  Unanticipated Adverse Device Effect  
VMT  Vitreomacular Traction  
VMA  Vitreomacular Adhesion  
 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Single -Arm Study Assessing the Effects  of Pneumatic Vitreolysis on 
Macular Hole  
Précis  Eyes with vitreomacular traction ( VMT ) and full-thickness  macular 
hole (MH)  will be enrolled into a non -random ized cohort treated 
with PVL to determine the proportion  with VMT release and MH 
closure and to assess factors associated with success .  
Investigational Device  Intraocular gas (C 3F8) injection  
Objectives  To obtain estimates of the proportion of eyes with  MH closure of the 
inner retinal layers  for eyes with VMT and full-thickness  MHs  
treated with PVL.  
Rationale  Understanding the rates of VMT release and MH closures in eyes 
with full-thickness  MH treated with PVL is of interest . Surgery 
would result in nearly 100% hole closure and VMT release, making 
vitrectomy a poor control group  choice . Spontaneous resolution o f 
MH is highly unlikely, making an observation arm unnecessary.  
Therefore, these eyes will be enrolled into a non -random ized cohort 
treated with PVL to assess the outcomes of treatment .  
Study Design  Single -arm study  
Number of Sites  Approximately 5 0 sites   
Endpoint  Primary Outcome:  Proportion of eyes with MH closure of the inner 
retinal layers  without rescue treatment  at 8 weeks . 
 
Key Secondary Outcomes: proportion  of eyes with central VMT 
release  without rescue treatment , proportion  of eyes with rescue 
treatment, mean change in visual acuity  
 
Key Safety Outcomes: retinal tear, retinal detachment, traumatic 
cataract,  cataract extraction, vitreous hemorrhage,  intraocular 
pressure  (IOP)  increase, and endophthalmitis . 
Population  Key Inclusion Criteria  
• Age ≥ 18 years.  
• Able and willing to avoid high altitude until gas resolution 
(approximately 6  to 8 weeks)  
• For phakic patients, a ble and willing to avoid supine 
positioning until gas resolution (approximately 6  to 8 weeks)  
• Able and willing to position face  down for at least 50% of the 
time for at least 4 days post -injection  
• At least 1 eye with:  
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 PARTICIPANT AREA  DESCRIPTION  
o Central v itreomacular adhesion  on OCT  that is no larger 
than 3000 microns , confirmed by  a central reading center  
o Full-thickness  MH that is ≤  250 microns  at the narrowest 
point  as measured on OCT, confirmed by a central 
Reading Center  
o Best corrected E-ETDRS visual acuity equivalent of 
20/25 to 20/400  
 
Key Exclusion Criteria   
• Other condition that might affect visual acuity during the 
course of the study (e.g. , retinal vein occlusion , advanced 
age-related macular degeneration , or macular edema induced 
by a condition other than VMT)  
• High level myopia ( -8.00 diopters or more  myopic if phakic 
or retinal abnormalities consistent with pathologic myopia if 
phakic or pseudophakic ) 
• Prior gas injection, ocriplasmin injection, or intraocular 
injection for any reason  
• Prior vitrectomy  
• History of advanced glaucoma that contraindicates intraocular 
gas injection  
Sample Size  50 eyes  
Treatment Group s C3F8 injection only  
Participant Duration  24 weeks  
Protocol 
Overview/Synopsis  1. Informed consent will be obtained.  
2. Eligibility will be assessed, including reading center 
confirmation of VMT and MH on OCT.  
3. Eligible eyes with VMT and MH will be treated with C 3F8 
injection.  
4. Follow -up visits will occur at 1, 4, 8, and 24 weeks and 
consist of visual acuity testing, ocular exam, and OCT . 
5. The primary outcome assessment will be the proportion  of 
eyes at 8 weeks  with full-thickness  MH closure of inner 
retinal layers  without rescue treatment .  
 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 SCHEMATIC OF STUDY DESIGN  
 Dropped IneligibleInformed Consent Obtained
Baseline Testing
Reading Center 
Review
Injection of C3F8
Gas (0.3 mL)
1 Week
4 Weeks
8 Weeks
(Primary 
Outcome)
24 WeeksDropped 
Ineligible
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19 SCHEDULE OF STUDY VISITS AND PROCEDURES  
 Enrollment  
Visit *  1, 4, 8, and 24  
weeks  
E-ETDRS best corrected visual acuity  a X X 
OCT b X X 
Eye exam c X X 
Reading center eligibility confirmation d  X  
Gas injection  X  
* All baseline testing must occur within 8 days prior to enrollment .  
a, Both eyes at all visits ; includes protocol refraction in study eye only at each visit and in both eyes at 
enrollment and 8 weeks . Electronic ETDRS  (E-ETDRS)  testing using the Electron ic Visual Acuity Tester 
that has been validated against 4 -meter chart ETDRS testing.  
b, Both eyes at baseline; study eye only at follow up visits.  
c, Both eyes at baseline; study eye only at each follow -up visit . Includes slit lamp exam (including 
assessme nt of lens), measurement of intraocular pressure, and dilated ophthalmoscopy.  Scleral depression 
is required at baseline to confirm eligibility. During follow up, the eye exam should be extensive enough 
to identify adverse events o f interest.  An extended ophthalmoscopy including a scleral depression is 
required at 1, 4, and 8 weeks.  
d, Reading center review of the OCT for eligibility must occur prior to enrollment . 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       1-1 CHAPTER 1:  BACKGROUND INFORMATION AND STUDY SYNOPSIS  1 
1.1. Introduction  2 
1.1.1 Vitreoretinal Interface Abnormalities  3 
Disorders of the vitreoretinal interface represent a spectrum of abnormalities that develop as the 4 
posterior hyaloid separates from the internal limiting membrane . Vitreomacular adhesion (VMA) 5 
occurs when  the posterior hyaloid remains attached to the internal limiting membrane centrally . 6 
Overall, about 1.5% of the population is estimated to have eye diseases caused by or associated 7 
with VMA.1 The incidence of VMA diagnoses is expected to increase with widespread use of 8 
spectral -domain optical coherence tomography (SD-OCT ). Vitreomacular traction (VMT) is 9 
diagnosed when VMA results in traction, distortion of retinal architecture, and patient 10 
symptomatology.2  11 
Advanced VMT can lead to macular holes (MH), in which tractional forces  create small full - 12 
thickness defects on the posterior fundus, often requiring surgical intervention.2 Regarding the 13 
incidence of idiopathic full -thickness macular holes, a population -based study showed idiopathic 14 
macular holes occur at an age and sex -adjusted incidence in 8.69 eyes per 100,000 population 15 
per year.3 The female to male ratio was determined to be 3.3 to 1, and bilateral idiopathic MHs 16 
occurred in 11.7% of patients and accounted for 20.9% of the affected eyes.3 In another study of 17 
a large population of patients with age -related macular degeneration (15,196 with non 18 
neovascular age-related macular degeneration (AMD ) and 12,716 with neovascul ar AMD), 0.7% 19 
were found to have MHs (1.1% with non-neovascular AMD and 0.3% with neovascular AMD).4 20 
Regarding MH prevalence globally, the Baltimore Eye Study repo rted a prevalence of 3.3 per 21 
1,000 persons  in Maryland ,5 the Beaver Dam  Eye Study showed a prevalence of 2.9 per 1,000 22 
persons  in Wisconsin , the Blue Mountains Eye Study showed a prevalence of 0.2 per 1,000 23 
persons in Australia,6 the Beijing Eye Study showed a prevalence of 0.9 per 1,000 persons in 24 
China ,7 and Sen et al. reported a prevalence of 1.7 per 1,000 persons in Southern India.8  25 
1.1.2 Treatment s for VMT  with Macular Hole  26 
For eyes with VMT with MH, prompt treatment  is indicated to restore central vision and prevent 27 
retinal detachment . In the MIVI -TRUST trial, ocriplasmin was successful in 60% in eyes with an 28 
MH of < 250 microns.9 However, there  have been multiple anecdotal reports of substantial 29 
ocular complications associated with intraocular administration of ocriplasmin,10-14 including 30 
transient vision  loss, persistent dyschromatopsia, electroretinographic abnormalities, subluxation 31 
of the crystalline lens likely related to zonulolysis, and disturbance or dehiscence of the ellipsoid 32 
layer documented by OCT. These adverse events have created major concer ns among many 33 
retinal surgeons in the clinical use of this drug.10-14 Therefore, vitrectomy is currently the first 34 
line therapy for VMT with MH . Although MH closure is usually successful after vitrectomy 35 
(approaching 100% success rate in several series), there are ass ociated downsides including cost, 36 
patient discomfort, length of time a large bubble resides in the eye, and possible adverse events  37 
such as endopthalmitis, retinal detachment, and cataract progression .15 38 
1.1.3 Pneumatic Vitreolysis  (PVL)  39 
Pneumatic vitreolysis (intraocular injection of expansile gas  to induce a posterior vitreous 40 
detachment [PVD]) has been suggested as a potential treatment alternative to vitrectomy or 41 
ocriplasmin for VM T with MH. In 1995, Chan et al . first demonstrated and reported the utility of 42 
intraocular gas  (C3F8) injection where 13 of 17 (76%) stage 1 or stage 2 macular holes closed 43 
after injection .16 Subsequently, Jorge et al . showed success in the induction of PVD ( 6 of 6 eyes ) 44 
and macular hole closure (5 of 6 eyes) with C 3F8 in small case series.17, 18 Mori et al .19 reported 5 45 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       1-2 of 10 eyes had hole closure after gas.19 Steinle et al . reported a success rate of 83% (25 of 30 46 
eyes) with C 3F8 gas in a retrospective case series for treatment of VMT syndrome.20 In a 2016 47 
retrospective review of 15 consecutive eyes receiving C 3F8 gas for pneumatic vitreolysis 48 
performed in 2 centers , Chan and Mein reported a success rate of 100% for VMT release and 49 
67% for hole closure in eyes with small stage  2 MH ≤ 250 microns .21 In 2019, Chan and Mein 50 
provided an update on this study and reported a success rate of 95.7% for VMT release and 51 
65.2% for hole closure among 23 eyes  with small stage 2 MH ≤ 250 microns .22 52 
1.2. Rationale  53 
Understanding the rates of MH closure and VMT release in eyes with full-thickness  macular 54 
holes treated with PVL  is of interest g iven the low cost and convenience of gas injection in the 55 
office setting  as well as a low rate of adverse events reported in prior retros pective studies . 56 
Although spontaneous macular hole closure is possible, this occurs infrequently .23 It is likely that 57 
eyes with these ch aracteristics would need prompt treatment, making randomization to a sham 58 
arm inappropriate . Prior studies have established the benefit of vitrectomy for treatment of 59 
macular holes , reporting  80 to 90% success rates in MH closure with associated visual ben efit, 60 
making vitrectomy an unnecessary (and expensive) control group choice.23-27 Therefore, these 61 
eyes will be enrolled into a non -randomized cohor t treated with PVL to assess the outcomes of 62 
treatment .  63 
 64 
If a large percentage of eyes can achieve MH closure with a simple in -office, low -cost 65 
procedure, while averting the invasiveness and expense of a vitrectomy for this condition, this 66 
would provide a viable first -line treatment option.  Even if this proposed study finds that PVL is 67 
only moderately suc cessful , physicians and patients may decide to attempt PVL in the office 68 
first, before proceeding with more costly, invasive surgery. Thus, even without a control group, 69 
the results from this study will provide data of value for physicians and patients to make 70 
informed decisions about treatment course.   71 
1.3 Study Objective s 72 
Primary  73 
1. To obtain estimates for the proportion of eyes with MH closure of the inner retinal layers  74 
for eyes with VMT and full-thickness  macular hole s treated with PVL   75 
1.4 Potential Risks and Be nefits of C3F8 Gas Injection  76 
1.4.1 Known Potential Risks  77 
Potential risks of C 3F8 gas injection include  the following : 78 
• Pain, discomfort, redness, or itching lasting for a few days is likely.  79 
• Subconjunctival hemorrhage or floaters will commonly occur as a result of the injection . The 80 
floaters are typically reduced after 6  to 8 weeks, but some floaters may persist.  81 
• Immediately following the injection, there may be elevation of IOP. Pressure  usually returns 82 
to normal spontaneously, but may need to be treated with topical drugs or a paracentesis to 83 
lower the pressure . The likelihood of permanent loss of vision from elevated IOP is less than 84 
1%. 85 
• Although it has not been reported in prior case series, endophthalmitis could theoretically 86 
develop . The risk of endop hthalmitis from other intraocular injections is less than 1%.  87 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       1-3 • A retinal tear or detachment could occur . The risk of retinal breaks or detachment after gas 88 
injection is approximately  5-13%. The risk of retinal detachment is increased if there are pre - 89 
existi ng peripheral retinal abnormalities such as lattice degeneration or cystic tufts.  90 
• There is a possibility of traumat ic cataract from the injection.  The risk of developing a 91 
cataract from the injection is <1%   92 
• If paracentesis is performed, there is a similar  risk of traumatic cataract from paracentesis . 93 
• If vitrectomy is required while gas is in the eye, there is high likelihood  of cataract formation 94 
during surgery that may require cataract removal  at the time of vitrectomy .  95 
• Limited and transient uveitis may develop after gas injection . Persistent uveitis is uncommon.  96 
• Limited transient conjunctival or episcleral hemorrhage is co mmon shortly after gas 97 
injection. It is usually inconsequential and clears spontaneously from a few days to a week or 98 
two.  99 
• Limited vitreous hemorrhage or opacities after gas injection is uncommon but may occur 100 
occasionally after gas injection, particularl y given a history of active anticoagulation therapy 101 
or predisposing risk for hemorrhage . If present, it usually resolves from a few days to a few 102 
months . Marked intraocular hemorrhage requiring a surgical intervention after gas injection 103 
is exceedingly rar e (< 1%).  104 
• Pre-existing epiretinal fibrosis may sometimes progress or new epiretinal fibrosis may 105 
develop after gas injection.  106 
• The development of excessive scarring on top of or under the retina after gas injection is 107 
exceedingly rare. When this occurs, it  is usually associated with advanced retinal 108 
detachment, which is also uncommon after gas injection.  109 
Additional risks if the participant does not follow post -injection instructions:  110 
• Intraocular pressure may increase if the patient experiences changes in el evation (i.e. travel 111 
by air or over mountain ranges) while the gas bubble is still present in the eye . 112 
• Loss of vision or blindness is possible if nitrous oxide anesthesia is administered with the gas 113 
bubble still present in the eye . 114 
• Incorrect head positioning following the gas injection may lead to glaucoma or cataracts . 115 
 116 
1.4.2 Known Potential Benefits  117 
Potential b enefits from participation in the study for eyes treated with  PVL include , improved 118 
visual acuity , improved quality of vision, closure of  MH, and avoidance of more invasive and 119 
expensive procedure s, i.e., vitrectomy, ocriplasmin.  120 
1.4.3 Risk Assessment  121 
The risk level is considered to be research involving greater than minimal risk.  122 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       1-4 1.5 General Considerations  123 
The study is being conducted in compliance with the policies described in the study policies 124 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 125 
the protocol described herein, and with the standards of Good Clinic al Practice (GCP).  126 
The DRCR Retina Network  procedures manuals provide details of the procedures .  127 
Data will be directly collected in electronic case report forms, which will be considered the 128 
source data.  129 
There is no restriction on the number of subjects t o be enrolled by each site towards the overall 130 
recruitment goal.  However, recruitment will be monitored on an ongoing basis and the sponsor 131 
can decide to place recruitment at a particular site on hold as needed.  132 
All consented participants will be logged.  The protocol is considered a significant risk device 133 
study because intraocular injection of C 3F8 is experimental for this indication . Therefore, an 134 
investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) i s 135 
required to conduc t the study .  136 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       2-1 CHAPTER 2:  STUDY P ARTICIPANT ELIGIBILITY AND ENROLLMENT  137 
2.1 Participant Recruitment and Enrollment  138 
Enrollment will proceed with the goal of at least 50 participants  deemed eligible by Reading 139 
Center and treated with C 3F8. Participants who have signed consent may be permitted to continue 140 
into the study,  if eligible , even if the enrollment  goal has been r eached.  141 
Study partic ipants will be recruited from approximately 50 clinical centers in the United States . 142 
Approximately 5 participants are expected to be enrolled  each month, resulting in 10 months of 143 
recruitment, for a total study duration of 16 months.  144 
All eligible participants will be included without regard to gender, race, or ethnicity . There is no 145 
restriction on the number of participant s to be enrolled by each site toward the overall 146 
recruitment goal.  147 
Potential eligibility may be assessed as part of a routine -care examination . Before  completing 148 
any procedures or collecting any data that are not part of usual care, written informed consent 149 
will be obtained.  150 
The study protocol will be discussed with the potential study participant by study staff . The 151 
potential study participant will be given the Informed Consent Form to read . Potential study 152 
participants will be encouraged to discuss the study with family members and their personal 153 
physicians(s) before deciding whether to participate in the study.  154 
As part of the informed consent process, each participant will be asked to sign an authorization 155 
for release of personal information . The investigator, or his or her designee, will review the 156 
study -specific information that will be collected and to whom that information will be disclosed . 157 
After speaking with the participant, questions will be answered about the details regarding 158 
authorization.  159 
2.2 Participant  Eligibility Criteria  160 
2.2.1 Participant -Level Criteria  161 
Inclusion  162 
To be eligible, the following inclusion criteria  must be met:  163 
1. Age ≥ 18 years  164 
• Participant s < 18 years old are not being included because the condition  is so rare in 165 
this age group  that the diagnosis may be questionable.   166 
2. At least one eye meets the study eye criteria listed in section 2.2.2  167 
3. Able and willing to provide informed consent  168 
4. Able and willing to avoid high altitude travel , including airline travel , until gas resolution 169 
(approximately 6  to 8 weeks)  170 
5. For phakic patients, a ble and willing to avoid supine position until gas resolution  171 
(approximate ly 6 to 8 weeks)  172 
6. Able and willing to position face  down for at least 50% of the time for at least 4 days post - 173 
injection (to facilitate macular hole closure)  174 
7. Able and willing  to wear wrist band that informs any medical personnel that the patient has a 175 
gas bubble in the eye  176 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       2-2 Exclusion  177 
A potential participant  is not eligible if any of the following exclusion criteria are present:  178 
8. A condition that, in the opinion of the investigator, would preclude participation in the study 179 
(e.g., unstable medical status  that might preclude completion of follow  up) 180 
9. Participat ion in an investigational trial within 30 days of enrollment  that involve s treatment 181 
with any drug or device that has not received regulatory approval for the indication being 182 
studied at the time of study entry  183 
• Note: study participants should not  receive a nother investigational drug  or device  while 184 
participating in the study  185 
10. Known contraindication  to any component of the treatment  186 
11. Known allergy to any drug used in the procedure  prep (including povidone iodine)  187 
12. Potential participant  is expecting to move out of the area of the clinical center to an area not 188 
covered by another clinical center during the 6 months  following enrollment  189 
13. Anticipated surgery requiring anesthesia within the 6 months following enrollment  190 
• Participants cannot receive nitrous oxide until gas resolution   191 
14. For women of child -bearing potential: pregnant at the time of enrollment  192 
• Women who are potential study participants should be questioned about the potential for 193 
pregnancy. Investigator jud gement may be used to determine when a pregnancy test is 194 
needed  195 
2.2.2 Study Eye Criteria  196 
The participant  must have at least one eye meeting all of the inclusion criteria and none of the 197 
exclusion criteria listed below.  198 
A participant can have only one study eye . If both eyes are eligible at the time of enrollment , the 199 
study eye will be selected by the investigator and participant before injection .  200 
The eligibility criteria for a study eye  are as follows:  201 
Inclusion  202 
a. Full-thickness macular hole that is ≤ 250 microns  at the narrowest point , confirmed by 203 
central reading center  204 
b. Central vitreomacular adhesion on OCT that is no larger than 3000 microns with visible 205 
separation of the vitreous on either side as seen on horizontal and vertical scans , confirmed 206 
by central reading center   207 
• Presence of epiretinal membrane is nei ther a requirement nor exclusion  208 
c. Visual acuity letter score of at least 19 (appr oximate Snellen equivalent 20/400  or better ) and 209 
at most 83 (20/25 or worse)  210 
Exclusion  211 
d. Other ocular condition that might affect visual acuity during the course of the study  or 212 
require intraocular treatment  (e.g., retinal vein occlusion , substantial age-related macular 213 
degeneration , or macular edema induced by a condition oth er than VMT)  214 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       2-3 • If diabetic retinopathy is present, severity level must be microaneurysms only or better (≤  215 
diabetic retinopathy  severity level 20) . 216 
• Presence of drusen is acceptable; however, eyes with geograph ic atrophy  or neovascular 217 
age-related macular degeneration  involving the macula are excluded .  218 
e. High level of myopia ( spherical equivalent of -8.00 diopters or more  myopic if phakic, or 219 
retinal abnormalities consistent with pathologic myopia if phakic or pseudophakic ) 220 
f. History of prior gas injec tion, ocriplasmin injection, or intraocular injection for any reason  221 
g. History of prior vitrectomy  222 
h. History of uncontrolled glaucoma  223 
• Intraocular  pressure must be <  30 mmHg , with no more than one topical glaucoma 224 
medication , and no documented glaucomatous fiel d loss for the eye to be eligible  225 
i. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular 226 
surgery, etc.) within prior 4 months or major ocular surgery anticipated within the next 6 227 
months following enrollment  228 
j. History of YAG capsulotomy performed within 4 months prior to enrollment  229 
k. Aphakia  or anterior chamber intraocular lens  230 
l. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or 231 
substantial blepharitis  232 
m. Uveitis   233 
n. Retinal history or pathology that might predispose an eye to an increased risk of retinal 234 
detachment from the procedure  235 
• Untreated retinal tears , not retinal holes,  are an exclusion.  It is up to the investigator to 236 
determine whether extent of lattice degener ation  or other pathology  might increase  the 237 
risk of retinal detachment  238 
o. Any contraindication to paracentesis (e.g. , history of narrow angle glaucoma)  239 
p. Lenticular or zonular instability  240 
2.3 Screening Evaluation and Baseline Testing  241 
After informed consent has been  signed, the potential participant will be evaluated for study 242 
eligibility through the e licitation of a medical history and  performance of an ocular  examination 243 
by study personnel to screen for exclusionary conditions.  244 
Individuals who do not initially meet  study eligibility requirements may be rescreened at a later 245 
date per investigator discretion.  246 
All testing does not need to be completed on the same day provided it is within the windows 247 
specified below . Reading Center confirmation of VMT with full-thickness  macular hole  on OCT 248 
must be completed prior to enrollment .  249 
2.3.1 Baseline Testing  Procedures  250 
The following procedures are needed to confirm eligibility and /or to serve as baseline measures 251 
for the study:   252 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       2-4 • If a procedure has been performed using t he study technique and by study certified 253 
personnel as part of usual care, then it does not need to be repeated specifically for the 254 
study if it was performed within the defined time windows specified below.  255 
• The testing procedures are detailed in the DRCR  Retina Network  Procedures Manuals . 256 
Visual acuity testing, ocular exam, and OCT will be performed by DRCR Retina 257 
Network  certified personnel.  258 
1. Self-repor ted demographics (date of birth, sex, race , and ethnicity)  259 
2. Medical history (pre -existing  medical condit ions, concomitant medications, as well as ocular 260 
diseases, surgeries, and treatment s) 261 
• Medical history will be obtained by medical charts if available at the enrolling site; 262 
otherwise, it will be self -reported  263 
3. Electronic -ETDRS visual acuity testing at 3 meters using the Electronic Visual Acuity Tester 264 
(including protocol refraction) in each eye  (within prior 8 days)  265 
4. Spectral -Domain OCT using Zeiss  Cirrus or Heidelberg Spectralis on each eye  (within  prior  266 
8 days)  267 
• OCT  scans of the study eye will be promptly  sent to the central reading center  for 268 
grading  and a participant cannot be enrolled  until reading center confirmation of 269 
eligibility has been received .  270 
5. Ocular examination on each eye including slit lamp, measur ement of IOP, lens assessment, 271 
and dilated ophthalmoscopy  (within prior 8 days )  272 
• Scleral depression to rule out any retinal tears pre -operatively will be required for the 273 
baseline eye exam to confirm eligibility .  274 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       3-1 CHAPTER 3:  BASELINE TREATMENT  275 
3.1 Treatment  276 
The C3F8 gas injection must be given on the day of enrollment .  277 
3.2 Injection  Procedure  278 
3.2.1 Intravitreous Injection Technique  279 
The injection is preceded by a povidone iodine prep  of the conjunctiva . A subconjunctival 280 
injection of lidocaine may b e administered at the discretion of the investigator . The injection will 281 
be performed using sterile technique . Pre-injection paracentesis should be considered due to the 282 
4x expansion of C 3F8 gas and the associated risk of shallowing of the anterior chamber . 283 
However, the choice of when or whether or not to do a paracentesis is ultimately at the 284 
investigator’s discretion.  The full injection procedure is described in the protocol -specific s tudy 285 
procedures manual . Topical antibiotics in the pre -, peri -, or post -injection period should not be 286 
used without prior approval from the Protocol Chair or Coordinating Center designee.  287 
3.2.2 Aqueous Sample Collection  288 
Participation in the ancillary sample collection component  is not a requirement for participation 289 
in this study . It is expected that sites with the capability  to ship intraocular fluids  will participate . 290 
At the time of consent into the main study, participants will have the option of signing the 291 
ancillary sample collecti on portion of the informed consent form to indicate their willingness to 292 
provide the sample for future use . If paracentesis is performed and participant consent is 293 
obtained, aqueous fluid already being drawn as part of paracentesis may be collected and shi pped 294 
on dry ice to a central laboratory for storage for future analyses.  Sites will be encouraged to 295 
collect samples when performing paracentesis, though sample collection will not be  required.  296 
Details regarding collection, sample labeling, storage, and sh ipment can be found in the 297 
procedures manual.  298 
3.3 Participant Instructions Post -Injection  299 
Participants will be given a post -injection instruction sheet informing them of all post -injection 300 
requirements and risks if they do not follow the se requirements. Participants will be instructed to 301 
position  face down for at least 50% of the time for at least 4 days post -injection . Participants will 302 
be instructed to avoid high altitude travel until  the surgeon confirms the gas bubble has cleared.  303 
Phakic participants will be asked to avoid the supine position and lie on one side or the stomach 304 
during sleeping hours until the surgeon confirms that the gas bubble has cleared . All participants 305 
will be instructed to wear a wristband to notify h ealthcare providers that they should not receive 306 
nitrous oxide anesthesia until the gas bubble has cleared. 307 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       4-1 CHAPTER 4:  FOLLOW -UP VISITS AND TESTING  308 
4.1 Study Visit s 309 
The schedule of protocol -specified follow -up visits  is as follows : 310 
• 1 week ( - 4 days to + 3  days)  311 
• 4 (±1) weeks  312 
• 8 (±2) weeks  313 
• 24 (±4) weeks  314 
4.1.1 Procedures at Study Visits  315 
The following procedures will be performed at each visit,  unless otherwise specified : 316 
1. E-ETDRS visual acuity testing (best corrected)  in each eye  317 
• A protocol refraction  in the study eye  is required at  each visit . Refraction in the non -study 318 
eye is only required at the 8 week visit. When a refraction is not performed, the most 319 
recently performed refraction is used for the testing.  320 
2. Spectral -Domain OCT using Zeiss Cirrus or  Heidelberg Spectralis on the study eye  321 
• The same machine type (Cirrus or Spectralis) used at baseline must  be used during follow  322 
up. 323 
3. Ocular exam  in the study eye only , including slit lamp examination with lens assessment, 324 
measurement of IOP, and dilated o phthalmoscopy  325 
• The eye exam should be extensive enough to identify adverse events of interest  326 
• An extended ophthalmoscopy including a  scleral depression is required at 1, 4, and 8 327 
weeks to identify any retinal tears or detachments  328 
All of the testing procedures do not need to be performed on the same day, provided that they are 329 
completed within the time window of a visit . If data from a testing procedure is unusable ( e.g., if 330 
OCT is ungradable), the partici pant may be asked to repeat the procedure during an additional 331 
visit, whether part of usual care or solely to repeat the procedure . 332 
4.1.2 Unscheduled  Visits  333 
Additional visits may occur as required for usual care of the study participant.  334 
Testing procedures at unscheduled visits are at investigator discretio n. However, it is 335 
recommended that procedures performed should follow the standard DRCR Retina Network  336 
protocol . 337 
4.2 Treatment During Follow  Up 338 
4.2.1 Criteria for Vitrectomy  339 
Vitrectomy should not be performed due to failure of macular hole  closure prior to 4 weeks 340 
without chair approval. Between 4 and 8 weeks, vitrectomy may only be performed (but is not 341 
required) if the macular hole size is not improving from  baseline. After 8 weeks, vi trectomy can 342 
be performed at investigator discretion.  343 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       4-2 4.2.2 Treatment for Other Conditions in the Study Eye  344 
An eye should not be enrolled that is anticipated to require intraocular treatment for another 345 
condition during the study.  If a condition requiring promp t treatment develops during follow  up, 346 
the treatment  is at investigator discretion .  347 
4.2.3 Treatment in the Non -Study Eye  348 
Treatment in the non -study eye is at investigator discretion , except that gas injection for VMT is 349 
not permitted in the non -study eye during  the study .  350 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       5-1 CHAPTER 5:  STUDY DEVICE  351 
5.1 Description of the Investigational Device  352 
Perfluoropropane C 3F8 is an inert gas under pressure and is administered by injection into the 353 
vitreous cavity . It was approved by the FDA in February 1993 (P900066) for the use of placing 354 
pressure on detached retina.  355 
 356 
5.2 Study Device Accountability Procedures  357 
Each participating site will use their own commercially available perfluoropropane C3F8. It must 358 
be stored at room temperature . Prior to each injection, t he investigator must confirm that the 359 
cylinder pressure is at least 50 psi and that the cylinder is not expired .  360 
5.3 Safety Measures  361 
Preparation of the p erfluoropropane C 3F8 injection will be performed in accordance with 362 
manufacturer labelling.  The full injec tion procedure is described in the protocol -specific study 363 
procedures manual.  364 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       6-1 CHAPTER 6:  ADVERSE EVENTS, DEVICE ISSUES, AND STOPPING RULES  365 
6.1 Adverse Events  366 
6.1.1 Definitions  367 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 368 
relationship between the adverse event and the device(s) under investigation (see section 6.  2 for 369 
reportable adverse events for this protocol) . 370 
Serious Adverse Event (SAE):  Any u ntoward medical occurrence that:  371 
• Results in death.  372 
• Is life -threatening (a non -life-threatening event which, had it been more severe, might 373 
have become life -threatening, is not necessarily considered a serious adverse event).  374 
• Requires inpatient hospitalizat ion or prolongation of existing hospitalization.  375 
• Results in persistent or significant disability , incapacity , or substantial disruption of the 376 
ability to conduct normal life functions ( e.g, sight threatening).  377 
• Is a congenital anomaly or birth defect.  378 
• Is co nsidered a significant medical event by the investigator based on medical judgment 379 
(e.g., may jeopardize the participant or may require medical  or surgical intervention to 380 
prevent one of the outcomes listed above).  381 
In general, an ocular adverse event shoul d be reported as serious (considered sight threatening) if 382 
it meets one of the following criteria:  383 
1. It causes a decrease of ≥ 30 letters in visual acuity compared with the last visual 384 
acuity measurement prior to onset (e.g. central retinal artery occlusion) . 385 
2. In the opinion of the investigator, it requires prompt surgical intervention (e.g. 386 
vitrectomy, vitreous tap, intravitre ous antibiotics , laser or cryosurgical retinopexy ) to 387 
prevent permanent loss of sight.  Examples include endophthalmitis , retinal tear,  or 388 
rhegmatogenous retinal detachment.  389 
Ocular adverse events that do not have the potential to result in permanent loss of sight would 390 
not be considered serious.  391 
Unanticipated Adverse Device Effect (UADE):  Any serious adverse effect on health or s afety or 392 
any life -threatening problem or death caused by, or associated with, a device, if that effect, 393 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 394 
investigational plan or application (including a supp lementary plan or application), or any other 395 
unanticipated serious problem associated with a device that relates to the rights, safety, or 396 
welfare of participants (21 CFR 812.3(s)).  397 
Adverse Device Effect (ADE):  Any untoward medical occurrence in a study pa rticipant which 398 
the device may have caused or to which the device may have contributed (Note that an Adverse 399 
Event Form is to be completed in addition to being reported on a Gas Injection Form ). 400 
Device Complaints:  A device complication or complaint is some thing that happens to a device or 401 
related to device performance, whereas an adverse event happens to a participant . A device 402 
complaint may occur independently from an AE, or along with an AE . An AE may occur without 403 
a device complaint or there may be an AE  related to a device complaint.  404 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       6-2 Device Malfunction:  Any failure of a device to meet its performance specifications or otherwise 405 
perform as intended . Performance specifications include all claims made in the labeling for the 406 
device . The intended performance  of a device refers to the intended use for which the device is 407 
labeled or marketed. (21 CFR 803.3)  408 
6.1.2 Reportable Adverse Events  409 
For this protocol, a reportable adverse event includes any untoward medical occurrence that 410 
meets one of the following criteria:  411 
1) an ocular AE (study eye) , 412 
2) a serious AE,  413 
3) an Adverse Device Effect  (ADE)  as defined in section 6.1.1 , or 414 
4) An AE occurring in association with a study procedure .  415 
All reportable Adverse Events whether  they are  volunteered by the participant, discovered by 416 
study personnel during questioning, or detected through physical examination, test ing procedure , 417 
or other means , will be reported on an Adverse Event Form online . Each Adverse Event Form is 418 
reviewed by the Med ical Monitor to verify the coding and the reporting that is required.  419 
6.1.3 Relationship of Adverse Event to Study Device  420 
The study investigator will assess the relationship of any adverse event to be related or unrelated 421 
by determining if there is a reasonable possibility that the adverse event may have been caused 422 
by the study device.  423 
To ensure consistency of adverse event causality assessments, investigators should apply the 424 
following general guideline when determining whether an adverse event is related:  425 
Yes 426 
There is a plausible temporal relationship between the onset of the adverse event and the study 427 
intervention, and the adverse event cannot be readily explained by the participant’s clinical state, 428 
intercurrent illness, or concomitant therapies; or the adve rse event follows a known pattern of 429 
response to the study intervention.  430 
No 431 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., 432 
preexisting medical condition, underlying disease, intercurrent illness, or concomit ant 433 
medication); or the adverse event has no plausible temporal relationship to study intervention.  434 
6.1.4 Intensity of Adverse Event  435 
The intensity of an adverse event will be rated on a 3 point scale: (1) mild, (2) moderate, or (3) 436 
severe . It is emphasized that the term severe is a measure of intensity: thus a severe adverse 437 
event is not necessarily serious . For example, itching for several days may be rated as severe, but 438 
may not be clini cally serious.  439 
MILD: Usually transient, requires no special treatment, and does not interfere with the 440 
participant’s daily activities.  441 
MODERATE: Usually causes a low level of inconvenience or concern to the participant and may 442 
interfere with daily activiti es, but is usually ameliorated by simple therapeutic measures.  443 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       6-3 SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic drug 444 
therapy or other treatment.  445 
6.1.5 Coding of Adverse Events  446 
Adverse events will be coded using the MedDRA  dictionary . The Medical Monitor will review 447 
the investigator’s assessment of causality and may agree or disagree . Both the investigator’s and 448 
Medical Monitor’s assessments will be recorded . The Medical Monitor will have the final say in 449 
determining the ca usality.  450 
Adverse events that continue after the participant’s discontinuation or completion of the study 451 
will be followed until their medical outcome is determined or until no further change in the 452 
condition is expected.  453 
6.1.6 Outcome of Adverse Event  454 
The outcom e of each reportable adverse event will be classified by the investigator as follows:  455 
COMPLETE RECOVERY/RESOLVED – The participant recovered from the AE/SAE without 456 
sequelae . Record the AE/SAE stop date.  457 
RECOVERED/RESOLVED WITH SEQUELAE – The event persist ed and had stabilized 458 
without change in the event anticipated . Record the AE/SAE stop date.  459 
FATAL – A fatal outcome is defined as the SAE that resulted in death . Only the event that was 460 
the cause of death should be reported as fatal . Adverse events and ser ious adverse events  that 461 
were ongoing at the time of death; however, were not the cause of death, will be recorded as 462 
resolved at the time of death.  463 
ONGOING – An ongoing AE/SAE is defined as the event was ongoing with an undetermined 464 
outcome.  465 
 An ongoing ou tcome for which further improvement or worsening is possible will 466 
require follow  up by the site in order to determine the final outcome of the AE/SAE.  467 
 An ongoing outcome that is medically stable (further change not expected) will be 468 
documented as such and will not require additional follow  up.  469 
 The outcome of an ongoing event at the time of death that was not the cause of death, 470 
will be updated and recorded as resolved with the date of death recorded as the stop 471 
date.  472 
All adverse events occurring during the  study and continuing at study termination should be 473 
followed by the participant’s physician and evaluated with additional tests (if necessary) until 474 
diagnosis of the underlying cause, or resolution . Follow -up information should be recorded on 475 
source docum ents.  476 
If any reported serious, related, or unexpected adverse events or UADEs are present when a 477 
participant completes the study, or if a participant is withdrawn from the study due to a  serious, 478 
related, or unexpected adverse event  of UADE , the participa nt will be contacted for re -evaluation 479 
within 2 weeks . If the adverse event has not resolved, additional follow  up will be performed as 480 
appropriate . Every effort should be made by the Investigator or delegate to contact the 481 
participant until the adverse ev ent has resolved or stabilized.  482 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       6-4 6.2 Reportable Device Issues  483 
All UADEs, ADEs, device complaints, and device malfunctions will be reported the Gas 484 
Injection Form irrespective of whether an adverse event occurred . 485 
6.3 Pregnancy Reporting  486 
If pregnancy occurs, the participant will remain in follow  up for the duration of the study . The 487 
occurrence of pregnancy will be reported on an AE Form.  488 
6.4 Timing of Event Reporting  489 
Serious adverse events and unexpected device -related adverse events must be r eported to the 490 
Coordinating Center within 24 hours via completion of the online case report  form.  491 
The Coordinating Center will notify all participating investigators of any adverse event that is 492 
serious, related, and unexpected. Notification will be made w ithin 10 days after the Coordinating 493 
Center becomes aware of the event.  494 
Each principal investigator is responsible for reporting serious study -related adverse events and 495 
abiding by any other reporting requirements specific to his  or her Institutional Review Board or 496 
Ethics Committee.  497 
Upon receipt of a UADE report, the JCHR will investigate the UADE and if indicated, report the 498 
results of the investigation to the sites’ IRBs, and the FDA within 10 working days of the JCHR 499 
becoming aware of  the UADE per 21CFR 812.46(b) (2) . The Medical Monitor must determine if 500 
the UADE presents an unreasonable risk to participants . If so, the Medical Monitor must ensure 501 
that all investigations, or parts of investigations presenting that risk, are terminated  as soon as 502 
possible but no later than 5 working days after the Medical Monitor makes this determination 503 
and no later than 15 working days after first receipt notice of the UADE.  504 
Device malfunctions will be handled by the site and manufacturer .  505 
6.5 Stopping C riteria  506 
6.5.1 Criteria for Suspending or Stopping Overall Study  507 
The Data and Safety Monitoring Committee (DSMC) will be informed of all unanticipated 508 
adverse device events that occur during the study and will review compiled safety data at 509 
periodic intervals . The DSMC may request suspension of study activities or stoppage of the 510 
study if deemed necessary based on the totality of safety data available.  511 
The study may be discontinued by the Executive Committee (with approval of the DSMC ) prior 512 
to the preplanned comp letion of follow  up for all study participants.  513 
6.6 Independent Safety Oversight  514 
A Data and Safety Monitoring Committee will approve the protocol, template Informed Consent 515 
Form, and substantive amendments and provide independent monitoring of adverse events . 516 
Cumulative adverse event data are tabulated semi -annually for review by the DSMC . Following 517 
each DSMC data review, a summary will be provided to IRBs . A list of specific adverse events 518 
to be reported expeditiously to the DSMC will be compiled and included as part of the DSMC 519 
Monitoring Plan  document .  520 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       6-5 6.7 Risks  521 
The potential risks associated with use of the study device are described in section 1.4.1.  522 
Additional risks are minor or infrequent and include  the following :  523 
Risks Related to Testing Procedures  524 
Many  of the testing procedures in this study are part of daily ophthalmologic practice in the 525 
United States and pose few if any known risks.  526 
• Dilating eye drops will be used as part of the exam . There is a small risk of inducing a 527 
narrow -angle glaucoma att ack from the pupil dilation . However, all participants will have 528 
had prior pupil dilation usually on multiple occasions and therefore the risk is extremely 529 
small .  530 
Risks Related Specifically to the Pre -Injection Preparation  531 
• There are potential side effect s to subconjunctival anesthetic, which are rare . They include, 532 
but are not limited to, the following: damage to the eyeball by the needle, damage to the optic 533 
nerve, double vision lasting 24 hours or more.  534 
• Complications associated with paracentesis are unc ommon, but may include uveitis, flat 535 
anterior chamber, corneal wound leak, hyphema, anterior vitreous prolapse, or pupillary 536 
block glaucoma  and cataract . Under certain circumstances, such complications may lead to 537 
vision loss.  538 
Risks if Pregnant  539 
According to the C 3F8 package insert, there are no known teratogenic effects when injected into 540 
the eye; however, caution should be used in pregnant women . Therefore, patients will not be 541 
allowed to participate in this study if pregnant.  Women who become p regnant during the study 542 
will be asked to stay in the study since there is no follow -up treatment with the investigational 543 
product.   544 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       7-1 CHAPTER 7:  MISCELLANEOUS CONSIDERATIONS  545 
7.1 Prohibited Medications, Treatments, and Procedures  546 
The participant will be instructed that nitrous oxide anesthesia must not be administered unless 547 
the investigator has confirmed that the gas bubble is no longer present.  Wristbands notifying 548 
healthcare providers of this will be given to participants following the intravit reous injection, and 549 
must  be worn until the investigator confirms that the gas bubble has cleared.  550 
7.2 Participant  Withdrawal  551 
Participation in the study is voluntary and a participant may withdraw at any time . If a study 552 
participant is considering withdrawal from the study, the principal investigator should personally 553 
speak to the individual about the reasons and every effort should be made to accommodate him 554 
or her .  555 
The goal for the study is to have as few losses to follow  up as possible . The Coor dinating Center 556 
will assist in the tracking of study participants who cannot be contacted by the site . The 557 
Coordinating Center will be responsible for classifying a study participant as lost to follow  up. 558 
For participants who withdraw, their data will be u sed up until the time of withdrawal.  559 
7.3 Discontinuation of Study  560 
The study may be discontinued by the Executive Committee (with approval of the DSMC ) prior 561 
to the preplanned completion of follow  up for all study participants.  562 
7.4 Confidentiality  563 
For security and confidentiality purposes, participants will be assigned an identifier that will be 564 
used instead of their name . Protected health information gathered for this study will be shared 565 
with the coordinating center, the Jaeb Center for Health Research in Tampa, F L. The 566 
Coordinating Center will be provided with contact information for each study participant . 567 
Permission to obtain such information will be included in the Informed Consent Form . The 568 
contact information may be maintained in a secure database and will be  maintained separately 569 
from the study data.  Phone contact from the Coordinating Center will be made with each study 570 
participant in the first month after enrollment . Additional phone contacts from the Coordinating 571 
Center will be made if necessary to facilit ate the scheduling of the study participant for follow - 572 
up visits . A participant -oriented newsletter and a study logo item may be sent once . Study 573 
participants will be provided with a summary of the study results in a newsletter format after 574 
completion of t he study by all participants .  575 
7.5 Participant Compensation  576 
Participant  compensation will be specified in the informed consent form. 577 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-1 CHAPTER 8:  STATISTICAL CONSIDERATIONS  578 
8.1 Statistical and Analytical Plans  579 
The approach to sample size and statistical analyses are summarized below. A detailed statistical 580 
analysis plan will be written and finalized prior to first review of data. The analysis plan synopsis 581 
in this chapter contains the framework of the anticipated final analysis plan.  582 
8.2 Statistical Hypotheses  583 
As this is a single -arm study, there are no formal statistical hypotheses that will be evaluated.  584 
8.3 Sample Size  585 
8.3.1 Outcome Projections  586 
Several case series provide estimates of stage 2 MH closure with PVL using C 3F8 gas. Chan et 587 
al. (1995)  reported MH closure in 3 of 6 eyes (50%) within 9 weeks of injection.16 Jorge et al. 588 
(2006) reported MH closure in 5 of  6 eyes (83%) one month after injection.17, 18 Finally, Chan et 589 
al. (2017) reported MH closure in 8 of 15 eyes (53%) within 9 weeks of injection.21 590 
8.3.2 Sample Size Estimates  591 
Table 1 shows anticipated confidence interval half widths for various sample sizes and true 592 
proportions of MH closure. These calculations assume a Type I error rate of 5%.  593 
Table 1: Anticipated Confidence Interval Half Widths  594 
MH Closure  Sample Size  
25 50 75 
85%  13.8%  9.9%  8.1%  
70%  16.9%  12.3%  10.2%  
50%  18.2%  13.4%  11.0%  
The sample size for this study was chosen for convenience and set at 50 eyes.  595 
8.4 Outcome Measures  596 
For the outcomes below, rescue treatment includes vitrectomy, ocriplasmin, or additional 597 
pneumatic vitreolysis during the course of the study.  598 
Primary Outcome:  599 
• Proportion of eyes with MH closure of the inner retinal layers* without rescue treatment 600 
at 8 weeks.  601 
o For purposes of description only, the distribution of eyes by the following 602 
categories at 8 weeks will be tabulated without statistical comparison:  603 
▪ MH closure without rescue treatment  604 
▪ MH closure with rescue treatment  605 
▪ No MH closure and no rescue treatment  606 
▪ No MH closure despite rescue treatment  607 
Secondary Outcomes:  608 
• Proportion of eyes with MH closure of the inner retinal layers* without rescue treatment 609 
through 24 weeks (time -to-event analysis).  610 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-2 • Proportion of eyes with central VMT release*  without rescue treatment through 24 weeks 611 
(time -to-event analysis).  612 
o For purposes of description only, the following will be tabulated without 613 
statistical comparison at 8 weeks and 24 weeks:  614 
▪ MH closure with central VMT release without rescue treatment  615 
▪ MH closu re without central VMT release without rescue treatment  616 
▪ MH closure with central VMT release with rescue treatment  617 
▪ MH closure without central VMT release with rescue treatment  618 
• Proportion of eyes with central VMT release and vitreopapillary traction release*  without 619 
rescue treatment through 24 weeks (time -to-event analysis).  620 
• Mean change in visual acuity letter score from baseline at 8 and 24 weeks.  621 
• Proportion of eyes with at least 10 -letter gain (increase) in visual acuity from baseline at 622 
8 and 24 weeks.  623 
• Proportion of eyes with at least 10 -letter loss (decrease) in visual acuity from baseline at 624 
8 and 24 weeks.  625 
• Proportion of eyes receiving rescue treatment before the 8 -week visit.  626 
• Proportion of eyes receiving rescue treatment before the 24 -week visit.  627 
o For purposes of description only, the following will be tabulated without 628 
statistical comparison:  629 
▪ Proportion of eyes receiving rescue treatment before the 24 -week visit or 630 
for which rescue treatment is planned at the 24 -week visit and medical 631 
record s confirm rescue treatment occurred within the subsequent 12 632 
weeks.  633 
▪ Type of rescue treatment.  634 
Exploratory Outcomes:  635 
• Proportion of eyes with MH closure of the inner retinal layers with outer retinal lucency* 636 
without rescue treatment at 8 and 24 weeks.28 637 
• Proportion of eyes with ellipsoid zone* integrity at 8 and 24 weeks . 638 
*Determined by masked grader at the central reading center.  639 
To ensure that statistical outliers do not have undue impact on analyses of continuous outcomes, 640 
change in continuous outcomes from baseline will be truncated to ± 3 standard deviations based 641 
on the overall mean and standard deviation at 8 weeks.  642 
8.5 Analysis  Cohorts  643 
• Intention -To-Treat (ITT) Analysis Cohort: all enrolled participants irrespective of 644 
treatment received . 645 
• Safety Analysis Cohort: all enrolled participants irrespective of treatment received .  646 
• Per Protocol Analysis Cohort: only participants that co mplete the initial treatment (PVL) 647 
and do not receive any non -protocol treatments during follow up. Vitrectomy performed 648 
according to the criteria in section 4.2.1 is considered per -protocol and will be included in 649 
this analysis.  650 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-3 The primary analysis will follow the ITT principle and include all enrolled participants.  651 
A per -protocol analysis will be performed to provide additional information regarding the 652 
magnitude of the treatment effect. The per -protocol analysis will only be performed if at least 653 
10% of  enrolled participants would be excluded by these criteria (e.g., 5 or more participants if 654 
exactly 50 are enrolled).  655 
The ITT analysis is considered the primary analysis. If the results of the per -protocol and ITT 656 
analyses give inconsistent results, the pe r-protocol analysis will be interpreted with caution. In 657 
this scenario, exploratory analyses will be performed to evaluate possible factors contributing to 658 
the difference.  659 
8.6 Analysis of the Primary Outcome  660 
The primary outcome of MH closure of the inner retinal layers without rescue treatment through 661 
8 weeks is a binary variable that is graded by the central reading center. The proportion of eyes 662 
meeting the primary outcome will be determined and the 95% Wils on (Score) confidence 663 
interval will be calculated.  664 
Since the chance of re -opening after closure before 8 or 24 weeks is highly unlikely, an eye with 665 
MH closure of the inner retinal layers without rescue treatment at any time prior to 24 weeks will 666 
be considered to have met the outcome through 24 weeks if the patient is lost to follow -up. 667 
Similarly, any eye receiving rescue treatment prior to 24 weeks will be considered not to have 668 
met the outcome through 24 weeks because rescue treatment has been given.  669 
Multiple imputation will be used to impute missing data for eyes lost to follow -up that did not 670 
have prior MH closure or rescue treatment documented. The imputation model will include 671 
presence of ERM within 1 mm of the center of the macula  at baseline and MH status at 1, 4, 8, 672 
and 24 weeks.  673 
A sensitivity analysis will be conducted using the same approach as above but without multiple 674 
imputation (i.e., complete -case analysis).  675 
8.7 Analysis of the Secondary and Exploratory Outcomes  676 
The ITT analys is cohort will be used for all secondary and exploratory outcomes.  677 
8.7.1 Secondary Efficacy Outcomes  678 
Macular hole closure of the inner retinal layers without rescue treatment through 24 weeks is a 679 
time-to-event outcome. A Kaplan -Meier curve will be constru cted and the cumulative probability 680 
with 95% confidence interval will be estimated for the final time point. Data from eyes not 681 
observed to have closure  or that receive rescue treatment will be censored on the date of their 682 
final visit.  683 
Central VMT release  without rescue treatment and central VMT release with vitreopapillary 684 
traction release without rescue treatment through 24 weeks are time -to-event outcomes graded by 685 
the central reading center and will be analyzed as above.  The latter  analysis will be adj usted for 686 
vitreopapillary traction status at baseline.  687 
Change  in visual acuity letter score from baseline at 8 and 24 weeks is a continuous outcome. 688 
The mean and 95% confidence interval will be calculated for each time point. Missing data will 689 
be imputed w ith multiple imputation. The imputation model will include presence of ERM 690 
within 1 mm of the center of the macula at baseline, baseline visual acuity, change in visual 691 
acuity from baseline at 1, 4, 8 and 24 weeks, and MH status at 1, 4, 8, and 24 weeks.  692 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-4 The proportion of eyes with at least 10 -letter gain (increase) or loss (decrease) in visual acuity 693 
from baseline at 8 and 24 weeks are binary variables. Wilson (Score) 95% confidence intervals 694 
will be calculated for each time point. The imputed data sets de scribed above for the mean 695 
change in visual acuity from baseline will be utilized.  696 
The proportion of eyes receiving rescue treatment before 8 and 24 weeks is a binary variable. 697 
Wilson (Score) 95% confidence intervals will be calculated for each time point.  Complete -case 698 
analysis (no imputation of missing data) will be used for this outcome.  699 
8.7.2 Exploratory Efficacy Outcomes  700 
The proportion of eyes with MH closure of the inner retinal layers with outer retinal lucency at 8 701 
and 24 weeks is a binary variable graded by the central reading center. Wilson (Score) 95% 702 
confidence intervals will be calculated  for each time point. Complete -case analysis (no 703 
imputation of missing data) will be used for this outcome.  704 
The proportion of eyes with ellipsoid zone integrity  at 8 and 24 weeks is a binary variable graded 705 
by the central reading center (loss of integrity and no loss of integrity). Wilson (Score) 95% 706 
confidence intervals will be calculated  for each time point. Complete -case analysis (no 707 
imputation of missing data) will be used for this outcome.  708 
8.8 Safety Analyses  709 
All reportable adverse events will be categorized as study eye or systemic. All events will be 710 
tabulated in a listing of each reported Medical Dictionary for Regulatory Activities (MedDRA) 711 
term a nd summarized over each MedDRA System Organ Class. All enrolled participants will be 712 
included in safety analyses.  713 
The frequency of each ocular adverse event occurring at least once per eye will be calculated. 714 
The proportion of eyes experiencing each outcom e will be calculated along with 95% Wilson 715 
(Score) confidence intervals. The following ocular adverse events are of primary interest:  716 
o Endophthalmitis  717 
o Retinal detachment  718 
o Retinal tear  719 
o Traumatic cataract  720 
o Cataract extraction in eyes phakic at baseline  721 
o Vitreous hemorrhage  722 
o Adverse IOP events (composite outcome)  723 
▪ Increase in IOP ≥ 10 mmHg from baseline (at a follow -up visit)  724 
▪ IOP ≥ 30 mmHg (at a follow -up visit)  725 
▪ Initiation of medication to lower IOP that was not in use at baseline  726 
▪ Glaucoma procedure  727 
The fre quency of each systemic adverse event occurring at least once per participant will be 728 
calculated. The following systemic adverse events are of primary interest:  729 
o Death  730 
o Serious adverse event (at least one)  731 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-5 The following systemic adverse events are of seconda ry interest:  732 
o For each MedDRA System Organ Class, proportion of participants with at least one 733 
serious adverse event  734 
In addition, the following will be tabulated:  735 
o Number of adverse events thought by investigator to be related to treatment  736 
8.9 Intervention Adherence  737 
Adherence will be defined as completion of PVL.  738 
8.10 Protocol Adherence and Retention  739 
Protocol deviations and visit completion rates (excluding deaths) will be tabulated.  740 
8.11 Baseline Descriptive Statistics  741 
Baseline characteristics will be ta bulated and summary statistics appropriate to the distribution 742 
will be reported.  743 
8.12 Planned Interim Analyses  744 
There is no formal interim analysis planned for this study. The Data and Safety Monitory 745 
Committee (DSMC) will review safety and outcome data approxim ately every 6 months while 746 
the study is ongoing.  747 
8.13 Subgroup Analyses  748 
Subgroup analyses, i.e., assessments of effect modification, will be conducted to detect factors 749 
associated with the primary outcome. These analyses will be considered exploratory.  750 
Subgrou p analyses will be conducted using logistic regression. The relative risk for the subgroup 751 
factor  (estimated using the method of Localio  et al.  200729), 95% confidence interval, and P 752 
value will be presented. To aid in interpretation of the relative risk, observed outcome 753 
proportions will be reported for each subgroup. Subgroup analyses will use data from eyes that 754 
complete the 8 -week visit or have MH closure or rescue treatment prior to 8 weeks (i.e., 755 
complete case analysis as described in section 8.6).  756 
The primary subgroup analysis will evaluate the effect of ERM presence within 1 mm of the 757 
center of the macula at baseline. Previous reports have suggested rates of VMT release and MH 758 
closure differ depending on the presence of ERM.  759 
Secondary subgroup analyses will include ERM presence at the site of vitreous adhesion, lens 760 
status (phakic or pseudophakic), components of VMT severity grade,30 length of adhesion on 761 
OCT (less than or equal to 1500 microns or greater than 1500 microns), and diabetes status (has 762 
diabetes or does not have diabetes).  763 
There are no data to suggest that the treatment effect will vary by sex or race/ethnicity. However, 764 
both of these factors will be evaluated in exploratory subgroup analyses as mandated by National 765 
Institutes of Health (NIH) guidelines.  766 
Subgroup factors will be analyzed as categorical and continuous or ordinal variables where 767 
possible. Secondary and exploratory subgroup analyses will only be conducted if there are at 768 
least 10 eyes in each subgroup.  769 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       8-6 8.14 Multiple Testing  770 
Because this is a single -arm study without tr eatment group comparisons, there will be no 771 
adjustments made for multiple testing.  772 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       9-1 CHAPTER 9:  DATA COLLECTION AND MONITORING  773 
9.1 Case Report Forms and Device Data  774 
The main study data are collected through electronic case report forms (CRFs) . These electronic 775 
CRFs from the study website are considered the primary source documentation.  776 
Each participating site will maintain appropriate medical and research records for this trial in 777 
compliance with ICH E6 and regulatory and institutional requireme nts for the protection of the 778 
confidentiality of participants.  779 
9.2 Study Records Retention  780 
Study documents should be retained for a minimum of 3 years following the NIH grant cycle for 781 
which the last visit was completed (expected to be December 31, 2026) . Thes e documents should 782 
be retained for a longer period, however, if required by local regulations . No records will be 783 
destroyed without the written consent of JCHR .  784 
9.3 Quality Assurance and Monitoring  785 
Designated personnel from the Coordinating Center will be res ponsible for maintaining quality 786 
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 787 
conducted and data are generated, documented , and reported in compliance with the protocol, 788 
Good Clinical Practice (GCP) , and the applicable regulatory requirements . Adverse events will 789 
be prioritized for monitoring.  790 
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 791 
of the study, consistent with the FDA “Guidance for Industry Oversigh t of Clinical 792 
Investigations — A Risk -Based Approach to Monitoring” (August 2013) . Study conduct and 793 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812.  794 
The most important data for monitoring at the site are participant eligibility and adverse events . 795 
Therefore, the RBM plan will focus on these areas . As much as possible, remote monitoring will 796 
be performed in real  time with on -site monitoring performed to evaluate the verity and 797 
completeness of the key site data . Element s of the RBM may include  the following : 798 
• Qualification assessment, training, and certification for sites and site personnel  799 
• Oversight of Institutional Review Board (IRB) coverage and informed consent 800 
procedures  801 
• Central (remote) data monitoring: validation o f data entry, data edits , audit trail, protocol 802 
review of entered data and edits, statistical monitoring, study closeout  803 
• On-site monitoring (site visits): source data verification, site visit report  804 
• Communications with site staff  805 
• Patient retention and visi t completion  806 
• Quality control reports  807 
• Management of noncompliance  808 
• Documenting monitoring activities  809 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       9-2 • Adverse event reporting and monitoring  810 
Coordinating Center representatives or their designees may visit the study facilities at any time in 811 
order to maintain  current and personal knowledge of the study through review of the records, 812 
comparison with source documents, or observation and discussion of the conduct and progress of 813 
the study.  814 
9.4 Protocol Deviations  815 
A protocol deviation is any noncompliance with the cli nical trial protocol, GCP, or procedure 816 
requirements . The noncompliance may be either on the part of the participant, the investigator, or 817 
the study site staff . As a result of deviations, corrective actions are to be developed by the site 818 
and implemented p romptly.  819 
The site primary investigator  and study staff are responsible for knowing and adhering to their 820 
IRB requirements . Further details about the handling of protocol deviations will be included in 821 
the monitoring plan. 822 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       10-1 CHAPTER 10:  ETHICS/PROTECT ION OF HUMAN PARTICIPANTS  823 
10.1 Ethics/Protection of Human Participants  Ethical Standard  824 
The investigator will ensure that this study is conducted in full conformity with Regulations for 825 
the Protection of Human Participants of Research codified in 45 CFR Part 46 , 21 CFR Part 50, 826 
21 CFR Part 56, and the ICH E6.  827 
10.2 Institutional Review Boards  828 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 829 
be submitted to the IRB for review and approval . Approval of both the protocol and the consent 830 
form must be obtained before any participant is enrolled . Any amendment to the protocol will 831 
require review and approval by the IRB before the changes are implemented to the study . All 832 
changes to the consent form will be IRB approv ed. In the event of an amendment, a 833 
determination will be made regarding whether previously consented participants need to be re - 834 
consented.  835 
10.3 Informed Consent Process  836 
10.3.1  Consent Procedures and Documentation  837 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 838 
the study and continues throughout the individual’s study participation . Extensive discussion of 839 
risks and possible benefits of participation will be provided to the participants and their families . 840 
Consent fo rms will be IRB -approved and the participant will be asked to read and review the 841 
document . The investigator will explain the research study to the participant and answer any 842 
questions that may arise . All participants will receive a verbal explanation in t erms suited to their 843 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 844 
research participants . Participants will have the opportunity to carefully review the written 845 
consent form and ask questions prior to si gning.  846 
The participants should have the opportunity to discuss the study with their surrogates or think 847 
about it prior to agreeing to participate . The participant will sign the informed consent document 848 
prior to any procedures being done specifically for t he study . The participants may withdraw 849 
consent at any time throughout the course of the trial . A copy of the informed consent document 850 
will be given to the participants for their records . The rights and welfare of the participants will 851 
be protected by emp hasizing to them that the quality of their medical care will not be adversely 852 
affected if they decline to participate in this study.  853 
10.3.2  Participant and Data Confidentiality  854 
Participant confidentiality is strictly held in trust by the participating investigato rs, their staff, 855 
and the JCHR and their agents . This confidentiality is extended to cover biological samples in 856 
addition to the clinical information relating to participants . Therefore, the study protocol, 857 
documentation, data, and all other information gen erated will be held in strict confidence . No 858 
information concerning the study or the data will be released to any unauthorized third party 859 
without prior written approval of the JCHR.  860 
The study monitor, other authorized representatives of the JCHR, or repre sentatives of the IRB 861 
may inspect all documents and records required to be maintained by the investigator, including 862 
but not limited to medical records (office, clinic, or hospital) and pharmacy records for the 863 
participants in this study . The clinical stud y site will permit access to such records.  864 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       10-2 The study participant’s contact information will be securely stored at each clinical site for 865 
internal use during the study . At the end of the study, all records will continue to be kept in a 866 
secure location for a s long a period as dictated by local IRB and institutional regulations.  867 
Study participant research data that is for the purposes of statistical analysis and scientific 868 
reporting will be transmitted to and stored at the coordinating center, the Jaeb Center for Health 869 
Research (JCHR) in Tampa, FL . This will not include the participant’s contact or identifying 870 
information . Rather, individual participants and their research data will be identified by a unique 871 
study identification number . The study data entry and study management systems used by 872 
clinical sites and by JCHR research staff will be secured and password protected . At the end of 873 
the study, all study databases will be de -identified and archived at JCHR.  874 
10.3.3  Future Use of Stored Specimens  875 
With the participant’s approval, de -identified biological samples will be stored at a central 876 
repository  for future research into the caus es, complications, and treatments of retinal diseases . 877 
The repository  will also be provided with a code -link that will allow linking the biological 878 
specimens with the phenotypic data from each participant, maintaining the masking of the 879 
identity of the par ticipant.  880 
During the conduct of the study, an individual participant can choose to withdraw consent to 881 
have biological specimens stored for future research . However, withdrawal of consent with 882 
regard to biosample storage will not be possible after the stud y is completed.   883 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       11-1 CHAPTER 11:  REFERENCES  884 
1. Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic 885 
vitreomacular adhesion. Retina.  2013;33(8):1503 -11. 886 
2. Duker JS, Kaiser PK, Binder S, e t al. The International Vitreomacular Traction Study 887 
Group classification of vitreomacular adhesion, traction, and macular hole. 888 
Ophthalmology.  2013;120(12):2611 -9. 889 
3. McCannel CA, Ensminger JL, Diehl NN, Hodge DN. Population -based incidence of 890 
macular hol es. Ophthalmology.  2009;116(7):1366 -9. 891 
4. Rao P, Yonekawa Y, Abbey A, al. e. Prevalence and surgical outcomes of macular hole 892 
in eyes with age -related macular degeneration. Retina 2017;1(2):158 -64. 893 
5. Rahmani B, Tielsch JM, Katz J, et al. The cause -specific prevalence of visual impairment 894 
in an urban population. The Baltimore Eye Survey. Ophthalmology.  1996;103(11):1721 - 895 
6. 896 
6. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of 897 
epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology.  898 
1997;104(6):1033 -40. 899 
7. Wang S, Xu L, Jonas JB. Prevalence of full -thickness macular holes in urban and rural 900 
adult Chinese: the Beijing Eye Study. Am J Ophthalmol.  2006;141(3):589 -91. 901 
8. Sen P, Bhargava A, Vijaya L, George R. Prevalence of idiopathic macular hole in adult 902 
rural and urban south Indian population. Clin Exp Ophthalmol.  2008;36(3):257 -60. 903 
9. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for 904 
vitreomacular traction and macular holes. N Engl J Med.  2012;367(7):606 -15. 905 
10. Fahim AT, Khan  NW, Johnson MW. Acute panretinal structural and functional 906 
abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol.  907 
2014;132(4):484 -6. 908 
11. Freund KB, Shah SA, Shah VP. Correlation of transient vision loss with outer retinal 909 
disruption fol lowing intravitreal ocriplasmin. Eye (Lond).  2013;27(6):773 -4. 910 
12. Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM. Does ocriplasmin affect the RPE - 911 
photoreceptor adhesion in macular holes? Br J Ophthalmol.  2015;99(5):635 -8. 912 
13. Kim JE. Safety and compl ications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe 913 
art thou? JAMA Ophthalmol.  2014;132(4):379 -80. 914 
14. Tibbetts MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocriplasmin: correlation 915 
of spectral -domain optical coherence tomography an d electroretinography. JAMA 916 
Ophthalmol.  2014;132(4):487 -90. 917 
15. Steel DH, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a 918 
comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond).  919 
2013;27 Suppl 1:S1 -21. 920 
16. Chan CK, We ssels IF, Friedrichsen EJ. Treatment of idiopathic macular holes by induced 921 
posterior vitreous detachment. Ophthalmology.  1995;102(5):757 -67. 922 
17. Costa RA, Cardillo JA, Morales PH, Jorge R, Uno F, Farah ME. Optical coherence 923 
tomography evaluation of idiopa thic macular hole treatment by gas -assisted posterior 924 
vitreous detachment. Am J Ophthalmol.  2001;132(2):264 -6. 925 
18. Jorge R, Costa RA, Cardillo JA, Uno F, Bonomo PP, Farah ME. Optical coherence 926 
tomography evaluation of idiopathic macular hole treatment by g as-assisted posterior 927 
vitreous detachment. Am J Ophthalmol.  2006;142(5):869 -71. 928 
Jaeb Center for Health Research  
 
Gas for Macular Hole Protocol V3.0 8 -12-19       11-2 19. Mori K, Saito S, Gehlbach PL, Yoneya S. Treatment of stage 2 macular hole by 929 
intravitreous injection of expansile gas and induction of posterior vitreous detachment. 930 
Ophtha lmology.  2007;114(1):127 -33. 931 
20. Steinle NC, Dhoot DS, Quezada Ruiz C, et al. Treatment of Vitreomacular Traction with 932 
Intravitreal Perfluoropropane (C3f8) Injection. Retina.  2017;37(4):643 -50. 933 
21. Chan CK, Crosson JN, Mein CE, Daher N. Pneumatic Vitreolys is for Relief of 934 
Vitreomacular Traction. Retina.  2017.  935 
22. Chan C. Pneumatic Vitreolysis for Resolving Focal Vitreomacular Traction: An Update 936 
on Clinical Outcome . 2019 Retina Society, 52nd Scientific Program, Landmark Hotel, 937 
London, UK, Sept 11 to 15, 20 19. 938 
23. Parravano M, Giansanti F, Eandi CM, Yap YC, Rizzo S, Virgili G. Vitrectomy for 939 
idiopathic macular hole. Cochrane Database Syst Rev.  2015(5):CD009080.  940 
24. Rao P, Yonekawa Y, Abbey A, Shah A, Wolfe J, Faia L. Prevalence and surgical 941 
outcomes of macul ar hole in eyes with age -related macular degeneration. 942 
Ophthalmololgy Retina.  2017;1(2):158 -64. 943 
25. Kumagai K, Furukawa M, Ogino N, Uemura A, Demizu S, Larson E. Vitreous surgery 944 
with and without internal limiting membrane peeling for macular hole repair. Retina.  945 
2004;24(5):721 -7. 946 
26. Spiteri Cornish K, Lois N, Scott NW, et al. Vitrectomy with internal limiting membrane 947 
peeling versus no peeling for idiopathic full -thickness macular hole. Ophthalmology.  948 
2014;121(3):649 -55. 949 
27. Tadayoni R, Gaudric A, Haouchi ne B, Massin P. Relationship between macular hole size 950 
and the potential benefit of internal limiting membrane peeling. Br J Ophthalmol.  951 
2006;90(10):1239 -41. 952 
28. Grewal DS, Reddy V, Mahmoud TH. Assessment of Foveal Microstructure and Foveal 953 
Lucencies Using  Optical Coherence Tomography Radial Scans Following Macular Hole 954 
Surgery. Am J Ophthalmol.  2015;160(5):990 -9 e1.  955 
29. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily 956 
computed indirectly from multivariable logistic re gression. J Clin Epidemiol.  957 
2007;60(9):874 -82. 958 
30. John VJ, Flynn HW, Jr., Smiddy WE, et al. Clinical course of vitreomacular adhesion 959 
managed by initial observation. Retina.  2014;34(3):442 -6. 960 
 961 